IPO Report: J&J’s Kenvue spinoff to hit IPO market this week in the biggest deal since late 2021


Johnson & Johnson’s consumer health company Kenvue is expected to hit the initial public offering market this week and mark the largest deal since late 2021.

Kenvue is parent to a host of household name brands, including Tylenol, Listerine, Band-Aid, Neutrogena and Nicorette.

“With over $2 billion in cash flow and a healthy 3.7% dividend,…

This article was originally published by Marketwatch.com. Read the original article here.

Previous articleAussie dollar, bond yields surge after surprise rate hike
Next article: Molson Coors adjusted profit jumps 82%


Please enter your comment!
Please enter your name here